Drugs / Ociperlimab
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04047862 | Aug 2019 → Aug 2024 | — | BeiGene | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05267054 | Apr 2022 → Aug 2024 | diffuse large B-cell lymphoma | BeiGene | Completed | No outcome recorded |
| Phase 29 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT05809895 | Sep 2023 → Jul 2029 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT05577702 | Mar 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05014815 | Nov 2021 → Sep 2024 | non-small cell lung carcinoma | BeiGene | Completed | Missed primary |
| Phase 2 | NCT05019677 | Sep 2021 → Dec 2024 | intrahepatic cholangiocarcinoma | Fudan University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04948697 | Aug 2021 → Feb 2024 | hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04952597 | Jul 2021 → Jul 2023 | small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04732494 | Mar 2021 → Feb 2023 | esophageal squamous cell carcinoma | BeiGene | Completed | Missed primary |
| Phase 2 | NCT04693234 | Feb 2021 → Jun 2022 | cervical cancer | BeiGene | Completed | Met primary |
| Phase 2 | NCT05023109 | Feb 2021 → Jan 2023 | biliary tract cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT05791097 | Jul 2023 → Dec 2027 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04866017 | Jun 2021 → Oct 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04746924 | May 2021 → May 2025 | non-small cell lung carcinoma | BeiGene | Terminated | Missed primary |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-03 | BeOne Medicines | Results BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program beonemedicines.com ↗
The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre-planned futility analysis. |
| 2022-09-10 | BeOne Medicines | Results BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer beonemedicines.com ↗
indications of anti-tumor activity and tolerable safety profile in a Phase 1 trial with tislelizumab in combination with chemotherapy and investigational anti-TIGIT antibody ociperlimab |
All press releases naming this drug 4 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ociperlimab | “Drug: Ociperlimab Ociperlimab 900mg IV Q3W” NCT05019677 ↗14“Drug: Ociperlimab Ociperlimab 900mg IV Q3W” NCT05023109 ↗ |
| Known as | BGB-A1217 | “BGB-A1217 (known as ociperlimab)” NCT04047862 ↗ |
| Action | Inhibit | “anti-TIGIT monoclonal antibody ociperlimab” PMID 37857528 ↗ Oct 2023 |
| Modality | Monoclonal antibody | “anti-TIGIT monoclonal antibody ociperlimab” PMID 37857528 ↗ Oct 2023 |
| Route | Intravenous | “Administered as an intravenous (IV) injection” NCT04047862 ↗ |
| Target | TIGIT | “binds to T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) with high affinity and specificity.” PMID 37857528 ↗ Oct 2023 |